Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BG-85738 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on BG-85738, a putative RAS inhibitor (Sep 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BG-85738 | BG 85738|BG85738 | RAS Inhibitor (Pan) 17 | Limited information is currently available on BG-85738, a putative RAS inhibitor (Sep 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07746141 | Phase I | BG-85738 + Tislelizumab BG-85738 + Cetuximab BG-85738 | A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations | Recruiting | AUS | 0 |